Edition:
United Kingdom

Opiant Pharmaceuticals Inc (OPNT.OQ)

OPNT.OQ on NASDAQ Stock Exchange Capital Market

15.74USD
16 Jul 2018
Change (% chg)

$-0.50 (-3.08%)
Prev Close
$16.24
Open
$16.73
Day's High
$16.91
Day's Low
$15.10
Volume
11,795
Avg. Vol
8,447
52-wk High
$51.90
52-wk Low
$12.75

Latest Key Developments (Source: Significant Developments)

Opiant Pharma Reports Financial Developments Related To Narcan Nasal Spray For Opioid Overdose
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS ANNOUNCES SIGNIFICANT FINANCIAL DEVELOPMENTS RELATED TO NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE.OPIANT PHARMACEUTICALS -EXPECTS ,BEGINNING Q1 2018, CO WILL RECEIVE 90% ROYALTY, MILESTONE PAYMENTS RELATED TO NARCAN SALES DIRECTLY FROM ADAPT PHARMA​.OPIANT PHARMACEUTICALS - ROYALTY & MILESTONE PAYMENTS DUE TO SWK HOLDINGS WILL NOW BE REDUCED TO 10%.  Full Article

Opiant Pharmaceuticals, Inc. Reports Qtrly ‍net Loss Per Common Share $2.77​
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS, INC. REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS.OPIANT PHARMACEUTICALS INC - QTRLY ‍NET LOSS PER COMMON SHARE $2.77​.  Full Article

Opiant pharmaceuticals says ‍may offer & sell its shares through Cantor Fitzgerald
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals says ‍may offer & sell through Cantor Fitzgerald its shares having aggregate offering price of up to $25 million - SEC filing​.  Full Article

Opiant Pharmaceuticals files for mixed shelf of upto $150 mln
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc files for mixed shelf of upto $150 million - sec filing ‍​.  Full Article

Opiant Pharmaceuticals reports Q4 loss per share $0.17‍​
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc reports fiscal fourth quarter and full year 2017 financial results and provides corporate update.Q4 revenue $3.75 million versus $300,000.‍Opiant Pharmaceuticals Inc - appointed David O'Toole as chief financial officer​.Opiant Pharmaceuticals Inc - qtrly loss per share $0.17‍​.  Full Article

BRIEF-Opiant Pharmaceuticals Reports Q1 Loss Per Share $3.68

* OPIANT PHARMACEUTICALS, INC. REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE